Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Elranatamab-bcmm
Synonyms
Therapy Description

Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Elranatamab-bcmm Elrexfio PF-06863135|PF06863135|PF 06863135 CD3 Antibody 93 TNFRSF17 Antibody 18 Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06057402 FDA approved Elranatamab-bcmm Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) (MagnetisMM15) Recruiting USA | FRA | CAN | AUS 1
NCT06421675 Phase II Elranatamab-bcmm Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE) Not yet recruiting CAN 0
NCT05014412 Phase II Elranatamab-bcmm MagnetisMM-9: Study of Elranatamab (PF-06863135) Monotherapy in Participants With Relapsed/Refractory Multiple Myeloma Active, not recruiting USA | GBR 2
NCT06152575 Phase III Dexamethasone + Elotuzumab + Pomalidomide Carfilzomib + Dexamethasone Bortezomib + Dexamethasone + Pomalidomide Elranatamab-bcmm MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Recruiting USA | CAN 1
NCT05020236 Phase III Elranatamab-bcmm Daratumumab + Dexamethasone + Pomalidomide Daratumumab + Elranatamab-bcmm MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5) Recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT06207799 Phase II Elranatamab-bcmm Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Not yet recruiting USA 0
NCT04649359 Phase II Elranatamab-bcmm Study of PF-06863135 Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb Active, not recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05462639 Expanded access Elranatamab-bcmm Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17) Available USA | CAN 0
NCT03269136 Phase I Elranatamab-bcmm Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma Completed USA | CAN 0
NCT06282978 Phase II Elranatamab-bcmm Phase II Study of Elranatamab as Single Agent for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Recruiting ESP 0
NCT06138275 Phase II Elranatamab-bcmm Elranatamab in R/R Multiple Myeloma Recruiting USA 0
NCT06183489 Phase II Elranatamab-bcmm Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM) Recruiting NLD | ITA | FRA 3
NCT05317416 Phase III Lenalidomide Elranatamab-bcmm Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 15


Additional content available in CKB BOOST